Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans
Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-c...
Gespeichert in:
| Veröffentlicht in: | Toxicological sciences Jg. 181; H. 1; S. 23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
27.04.2021
|
| Schlagworte: | |
| ISSN: | 1096-0929, 1096-0929 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-cleaved K18 (ccK18), osteopontin (OPN), macrophage colony-stimulating factor (MCSF), MCSF receptor (MCSFR), and microRNA-122 (miR-122) in comparison to the traditional biomarker alanine aminotransferase (ALT). Biomarkers were evaluated individually and as a multivariate model in a cohort of acetaminophen overdose (n = 175) subjects and were further tested in cohorts of healthy adults (n = 135), patients with liver damage from various causes (n = 104), and patients with damage to the muscle (n = 74), kidney (n = 40), gastrointestinal tract (n = 37), and pancreas (n = 34). In the acetaminophen cohort, a multivariate model with GLDH, K18, and miR-122 was able to detect DILI more accurately than individual biomarkers alone. Furthermore, the three-biomarker model could accurately predict patients with liver injury compared with healthy volunteers or patients with damage to muscle, pancreas, gastrointestinal tract, and kidney. Expression of K18, GLDH, and miR-122 was evaluated using a database of transcriptomic profiles across multiple tissues/organs in humans and rats. K18 mRNA (Krt18) and MiR-122 were highly expressed in liver whereas GLDH mRNA (Glud1) was widely expressed. We performed a comprehensive, comparative performance assessment of 7 promising biomarkers and demonstrated that a 3-biomarker multivariate model can accurately detect liver injury. |
|---|---|
| AbstractList | Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-cleaved K18 (ccK18), osteopontin (OPN), macrophage colony-stimulating factor (MCSF), MCSF receptor (MCSFR), and microRNA-122 (miR-122) in comparison to the traditional biomarker alanine aminotransferase (ALT). Biomarkers were evaluated individually and as a multivariate model in a cohort of acetaminophen overdose (n = 175) subjects and were further tested in cohorts of healthy adults (n = 135), patients with liver damage from various causes (n = 104), and patients with damage to the muscle (n = 74), kidney (n = 40), gastrointestinal tract (n = 37), and pancreas (n = 34). In the acetaminophen cohort, a multivariate model with GLDH, K18, and miR-122 was able to detect DILI more accurately than individual biomarkers alone. Furthermore, the three-biomarker model could accurately predict patients with liver injury compared with healthy volunteers or patients with damage to muscle, pancreas, gastrointestinal tract, and kidney. Expression of K18, GLDH, and miR-122 was evaluated using a database of transcriptomic profiles across multiple tissues/organs in humans and rats. K18 mRNA (Krt18) and MiR-122 were highly expressed in liver whereas GLDH mRNA (Glud1) was widely expressed. We performed a comprehensive, comparative performance assessment of 7 promising biomarkers and demonstrated that a 3-biomarker multivariate model can accurately detect liver injury. Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-cleaved K18 (ccK18), osteopontin (OPN), macrophage colony-stimulating factor (MCSF), MCSF receptor (MCSFR), and microRNA-122 (miR-122) in comparison to the traditional biomarker alanine aminotransferase (ALT). Biomarkers were evaluated individually and as a multivariate model in a cohort of acetaminophen overdose (n = 175) subjects and were further tested in cohorts of healthy adults (n = 135), patients with liver damage from various causes (n = 104), and patients with damage to the muscle (n = 74), kidney (n = 40), gastrointestinal tract (n = 37), and pancreas (n = 34). In the acetaminophen cohort, a multivariate model with GLDH, K18, and miR-122 was able to detect DILI more accurately than individual biomarkers alone. Furthermore, the three-biomarker model could accurately predict patients with liver injury compared with healthy volunteers or patients with damage to muscle, pancreas, gastrointestinal tract, and kidney. Expression of K18, GLDH, and miR-122 was evaluated using a database of transcriptomic profiles across multiple tissues/organs in humans and rats. K18 mRNA (Krt18) and MiR-122 were highly expressed in liver whereas GLDH mRNA (Glud1) was widely expressed. We performed a comprehensive, comparative performance assessment of 7 promising biomarkers and demonstrated that a 3-biomarker multivariate model can accurately detect liver injury.Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-cleaved K18 (ccK18), osteopontin (OPN), macrophage colony-stimulating factor (MCSF), MCSF receptor (MCSFR), and microRNA-122 (miR-122) in comparison to the traditional biomarker alanine aminotransferase (ALT). Biomarkers were evaluated individually and as a multivariate model in a cohort of acetaminophen overdose (n = 175) subjects and were further tested in cohorts of healthy adults (n = 135), patients with liver damage from various causes (n = 104), and patients with damage to the muscle (n = 74), kidney (n = 40), gastrointestinal tract (n = 37), and pancreas (n = 34). In the acetaminophen cohort, a multivariate model with GLDH, K18, and miR-122 was able to detect DILI more accurately than individual biomarkers alone. Furthermore, the three-biomarker model could accurately predict patients with liver injury compared with healthy volunteers or patients with damage to muscle, pancreas, gastrointestinal tract, and kidney. Expression of K18, GLDH, and miR-122 was evaluated using a database of transcriptomic profiles across multiple tissues/organs in humans and rats. K18 mRNA (Krt18) and MiR-122 were highly expressed in liver whereas GLDH mRNA (Glud1) was widely expressed. We performed a comprehensive, comparative performance assessment of 7 promising biomarkers and demonstrated that a 3-biomarker multivariate model can accurately detect liver injury. |
| Author | Arat, Seda Vaidya, Vishal S Hyde, Craig Ramaiah, Shashi K Zong, Qing Aithal, Guruprasad P Wang, Jianying Martin, Matt Llewellyn, Heather P Potter, David Warner, Roscoe Peng, Qinghai Masek-Hammerman, Katherine Wang, Zhenyu Johnson, Kent Kullak-Ublick, Gerd A Dear, James W |
| Author_xml | – sequence: 1 givenname: Heather P surname: Llewellyn fullname: Llewellyn, Heather P organization: Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121 USA – sequence: 2 givenname: Vishal S surname: Vaidya fullname: Vaidya, Vishal S organization: Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, USA – sequence: 3 givenname: Zhenyu surname: Wang fullname: Wang, Zhenyu organization: Early Clinical Development, Pfizer, Inc., Cambridge, Massachusetts 02139, USA – sequence: 4 givenname: Qinghai surname: Peng fullname: Peng, Qinghai organization: Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121 USA – sequence: 5 givenname: Craig surname: Hyde fullname: Hyde, Craig organization: Early Clinical Development, Pfizer, Inc., Cambridge, Massachusetts 02139, USA – sequence: 6 givenname: David surname: Potter fullname: Potter, David organization: Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, USA – sequence: 7 givenname: Jianying surname: Wang fullname: Wang, Jianying organization: Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121 USA – sequence: 8 givenname: Qing surname: Zong fullname: Zong, Qing organization: Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121 USA – sequence: 9 givenname: Seda surname: Arat fullname: Arat, Seda organization: Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340 USA – sequence: 10 givenname: Matt surname: Martin fullname: Martin, Matt organization: Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340 USA – sequence: 11 givenname: Katherine surname: Masek-Hammerman fullname: Masek-Hammerman, Katherine organization: Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, USA – sequence: 12 givenname: Roscoe surname: Warner fullname: Warner, Roscoe organization: Michigan Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA – sequence: 13 givenname: Kent surname: Johnson fullname: Johnson, Kent organization: Michigan Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA – sequence: 14 givenname: Gerd A surname: Kullak-Ublick fullname: Kullak-Ublick, Gerd A organization: Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland – sequence: 15 givenname: Guruprasad P surname: Aithal fullname: Aithal, Guruprasad P organization: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK – sequence: 16 givenname: James W surname: Dear fullname: Dear, James W organization: Pharmacology, Therapeutics and Toxicology, Centre for Cardiovascular Science, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK – sequence: 17 givenname: Shashi K surname: Ramaiah fullname: Ramaiah, Shashi K organization: Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33483742$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1PAjEQxRuDkQ-9ejQ9elnp13Z3j4ooJCSaoOdNt-1iYWmh7RL5712CJp7mzeQ3k_dmCHrWWQ3ALUYPGBV0HN13kGa8qUWFEL0Ag27KE1SQovdP98EwhDVCGHNUXIE-pSynGSMDsJ8eRNOKaOwKxi8Nl9oGE83BxCMUVsHlTktTG3nqXQ3fvduacIInxsu2OS8-GbcVfqN9gNHBZyNW1gUNF-agPZzbdeuP0Fg4a7fChmtwWYsm6JvfOgKfL9OPySxZvL3OJ4-LRFJexERQpTJGZZpTkQuhMdd5l7CStVQq1SgjSgpCUsYlT9MKM4wYQQpTmuYk5ZyMwP357s67fatDLDvnUjeNsNq1oSQsRyyjWc469O4XbautVuXOmy7Psfx7E_kB93RuDg |
| CitedBy_id | crossref_primary_10_1007_s00204_024_03954_5 crossref_primary_10_1038_s41467_025_61600_9 crossref_primary_10_20538_1682_0363_2024_4_177_186 crossref_primary_10_1093_toxsci_kfae031 crossref_primary_10_3390_gastroent15040075 crossref_primary_10_1186_s41512_023_00155_z crossref_primary_10_3389_fphys_2021_703370 crossref_primary_10_1007_s40264_021_01109_4 crossref_primary_10_1002_adhm_202404981 crossref_primary_10_1080_17425255_2023_2259787 crossref_primary_10_1080_19390211_2024_2327546 crossref_primary_10_12688_f1000research_94159_1 crossref_primary_10_3390_ijms23116049 crossref_primary_10_3390_livers3040039 crossref_primary_10_1016_j_cgh_2022_12_040 crossref_primary_10_1111_bcp_16371 crossref_primary_10_1016_j_nmd_2023_11_005 crossref_primary_10_1080_15563650_2023_2293452 crossref_primary_10_1289_EHP9467 crossref_primary_10_1093_toxsci_kfae143 crossref_primary_10_1007_s00204_023_03460_0 crossref_primary_10_1124_dmd_121_000732 crossref_primary_10_1038_s41467_023_36858_6 crossref_primary_10_1080_15563650_2023_2259089 crossref_primary_10_1080_14728222_2022_2133699 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/toxsci/kfab003 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1096-0929 |
| ExternalDocumentID | 33483742 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .ZR 0R~ 123 18M 1TH 1~5 29Q 2WC 4.4 48X 4G. 53G 5RE 5VS 5WA 5WD 7-5 70D A8Z AABZA AACTN AACZT AAHBH AAIMJ AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAVLN ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABMNT ABNHQ ABNKS ABPTD ABQLI ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTJ ACUTO ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEGXH AEJOX AEKSI AELWJ AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXEN AGINJ AGKEF AGQXC AGSYK AHMMS AHXPO AIJHB AJEEA AKHUL AKRWK AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BSWAC BTRTY BVRKM CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EDH EE~ EMOBN F5P F9B FDB FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HW0 HZ~ I-F IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 N9A NGC NLBLG NOMLY NOYVH NPM NQ- NU- O-L O9- OAWHX OBOKY OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OWPYF P2P PAFKI PEELM Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SV3 TJX TLC TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~02 ~91 7X8 AAYWO ABPQP ABXZS ADNBA AHGBF AJBYB AJNCP ALXQX ESTFP JXSIZ |
| ID | FETCH-LOGICAL-c369t-a3dd743c583a8aae16e8003bcfcdd5e072dca22546c655b1410420d1335825662 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000699370800004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1096-0929 |
| IngestDate | Sat Sep 27 23:26:40 EDT 2025 Wed Feb 19 02:28:17 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | diagnosis microRNA glutamate dehydrogenase keratin-18 liver |
| Language | English |
| License | The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c369t-a3dd743c583a8aae16e8003bcfcdd5e072dca22546c655b1410420d1335825662 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 33483742 |
| PQID | 2480473784 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2480473784 pubmed_primary_33483742 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-27 |
| PublicationDateYYYYMMDD | 2021-04-27 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Toxicological sciences |
| PublicationTitleAlternate | Toxicol Sci |
| PublicationYear | 2021 |
| SSID | ssj0011609 |
| Score | 2.471367 |
| Snippet | Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 23 |
| Title | Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33483742 https://www.proquest.com/docview/2480473784 |
| Volume | 181 |
| WOSCitedRecordID | wos000699370800004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1da9RAFL1oKyIUP1ar9YsrSJ8aNpnP5Em0tijYJWCFfVsmdyayLU3azSr233snSd0nQfAlJJBAwr2ZOTP33HMA3jqX6YoymejM20Qp4n_Ok05CbWWgqlAupd5sws5m-XxelOOGWzfSKm_GxH6g9i3FPfKpUHmqrLS5end5lUTXqFhdHS00bsO2ZCgTs9rON1WEzPQUjyyNRFvGAX9EG-V03f7iKWZ6XruY13-Hl_00c_zgf1_wIdwfASa-HzLiEdwKzQTunowl9Ansl4NY9fUBnm56r7oD3MdyI2N9PYGdYUcPh0alx3B1NAqDN9-RUSN-jdT3wXsCXeOxd7KPehR83dZYrlpOoXjz4XJFvUkYn39YtheRELTqcN3ix4HnF_BLZIfg5-aMI4zLBvvSQvcEvh0fnR5-SkbDhoSkKdaJk94zIiGdS5c7FzITGI_KimryXofUCk9ORAV-MlpXkWKqROp5max5oWqM2IWtpm3CM0CiwtcM9oKxlRKuzn1GNlhjyOpCZmoP3txEYcFfE6scrgntj26xicMePB1CubgclDsWse1YWiWe_8PTL-CeiPyVVCXCvoTtmoeD8Aru0M_1slu97jONj7Py5DcqeODh |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+the+Sensitivity+and+Specificity+of+Promising+Circulating+Biomarkers+to+Diagnose+Liver+Injury+in+Humans&rft.jtitle=Toxicological+sciences&rft.au=Llewellyn%2C+Heather+P&rft.au=Vaidya%2C+Vishal+S&rft.au=Wang%2C+Zhenyu&rft.au=Peng%2C+Qinghai&rft.date=2021-04-27&rft.issn=1096-0929&rft.eissn=1096-0929&rft.volume=181&rft.issue=1&rft.spage=23&rft_id=info:doi/10.1093%2Ftoxsci%2Fkfab003&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1096-0929&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1096-0929&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1096-0929&client=summon |